Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) just unveiled an announcement.
Artrya Limited has issued 500,000 fully paid ordinary shares following the exercise of vested options by director Bernie Ridgeway, and will seek quotation of the new shares on the ASX alongside an updated director interest notice. The company has also lodged a secondary trading (cleansing) notice confirming the shares were issued without a prospectus and that it remains compliant with its continuous disclosure obligations, supporting orderly trading for existing and new investors.
The share issue modestly increases Artrya’s free float and reflects director participation in the company’s equity, signalling internal confidence in its AI-driven cardiac imaging platform. By affirming there is no excluded information under the Corporations Act, Artrya aims to provide regulatory clarity and maintain transparency for the market as it progresses commercialisation of its Salix technology.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$6.27 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company that develops AI-powered solutions to improve detection and management of coronary artery disease. Its Salix cloud platform analyses coronary CT scans to identify key biomarkers of heart disease, supporting more accurate and efficient diagnosis, with regulatory and commercial efforts underway in key international markets.
Average Trading Volume: 511,635
Technical Sentiment Signal: Buy
Current Market Cap: A$621.3M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.